Novavax Soars on Strong Q4 Revenue Beat

Novavax (NASDAQ:NVAX) earnings for fiscal fourth quarter of 2019 have NVAX stock heading higher after-hours Wednesday. This is despite its diluted losses per share of -$1.13 missing Wall Street’s estimate of -$1.06. The vaccine company’s revenue of $8.82 million, on the other hand, easily beats out analysts’ estimates of $2.06 million.

• Diluted per-share losses are 56.03% better than the -$2.57 from the fiscal fourth quarter of 2018.
• Revenue for the quarter is 43.88% higher than the $6.13 million reported in the same period of the year prior.
• Operating loss of -$28.71 million is a 38.27% improvement year-over-year from -$46.51 million.
• The Novavax earnings report also includes a net loss of -$31.83 million, 35.48% better than the -$49.33 million reported during the same time last year.

Novavax Earnings: NVAX Stock Soars 8% on Strong Q4 Revenue Beat